Jonathan E. Lim, President, CEO at HALOZYME THERAPEUTICS INC (HALO), sold 20,000 shares at $8.31 ($165K) on 2007-11-30, disclosed to the SEC on 2007-12-04.
Scheduled sale ($165k) by President, CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.06 | 100 | $806 | 0.5% |
| 2 | $8.16 | 800 | $7K | 4.0% |
| 3 | $8.17 | 602 | $5K | 3.0% |
| 4 | $8.18 | 1,200 | $10K | 6.0% |
| 5 | $8.19 | 298 | $2K | 1.5% |
| 6 | $8.20 | 1,440 |
| $12K |
| 7.2% |
| 7 | $8.21 | 3,360 | $28K | 16.7% |
| 8 | $8.23 | 1,600 | $13K | 8.0% |
| 9 | $8.25 | 5,100 | $42K | 25.5% |
| 10 | $8.26 | 300 | $2K | 1.5% |
| 11 | $8.27 | 400 | $3K | 2.0% |
| 12 | $8.29 | 100 | $829 | 0.5% |
| 13 | $8.30 | 2,132 | $18K | 10.7% |
| 14 | $8.31 | 2,568 | $21K | 12.9% |
| Total | $8.24 avg | 20,000 | $165K | 100% |
| Filing → |
| ERAS | BUY | 2023-06-08 | $275K | — | Filing → |
| ERAS | BUY | 2023-03-28 | $284K | — | Filing → |
| ERAS | BUY | 2023-01-10 | $232K | — | Filing → |